{"id":908062,"date":"2025-11-10T20:30:49","date_gmt":"2025-11-11T01:30:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myomo-reports-third-quarter-2025-financial-and-operating-results\/"},"modified":"2025-11-10T20:30:49","modified_gmt":"2025-11-11T01:30:49","slug":"myomo-reports-third-quarter-2025-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myomo-reports-third-quarter-2025-financial-and-operating-results\/","title":{"rendered":"Myomo Reports Third Quarter 2025 Financial and Operating Results"},"content":{"rendered":"

<\/p>\n

Myomo Reports Third Quarter 2025 Financial and Operating Results<\/b><\/p>\n

Revenue of $10.1 million
\n
<\/i>229 authorizations and orders, highest number this year
\n
<\/i>Reiterates full year revenue guidance of $40 million to $42 million<\/i><\/p>\n

Conference call begins today at 4:30pm Eastern time<\/i><\/p>\n

BURLINGTON, Mass.–(BUSINESS WIRE<\/a>)–Myomo, Inc. (NYSE American: MYO)<\/b> (\u201cMyomo\u201d or the \u201cCompany\u201d), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025.<\/p>\n

\n\u201cThird quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics (“O&P”) revenues at record levels. Revenue increased while operating expenses decreased on a sequential basis, reflecting our focus on improving operating leverage,” said Paul R. Gudonis, Myomo’s Chairman and Chief Executive Officer. “We also achieved our strongest quarter of the year for authorizations and orders, while the marketing changes we implemented during the quarter contributed to a sequential decline in cost per pipeline add of 5%.”<\/p>\n

\n“We believe the key to lowering cost per pipeline add is strengthening relationships with the therapists and physicians that are integrated into the continuum of care our patients receive, while reducing our reliance on advertising for lead generation. Under this new program, called MyoConnect, which is expected to generate recurring patient referrals, our clinical team engages with therapists and physicians nationwide to expand the network of healthcare professionals who understand the benefits of the MyoPro. We view MyoConnect as a more scalable means of growing our patient pipeline, while reducing cost per pipeline add and improving pipeline quality, and we are encouraged by the early results,” added Gudonis. “We are also seeing growth from the O&P channel as more clinicians add the MyoPro to their product offerings and begin building their own patient pipelines”<\/p>\n

Recent Operational and Strategic Highlights:<\/b><\/p>\n